Assessment of tumor hypoxia in laryngeal cancer with 18F-fluoroazomycin arabinoside (18F-FAZA)-PET/CT scanning, oxygen-enhanced MRI (OE-MRI) and immunohistochemistry
Completed
- Conditions
- laryngeal cancervocal cord cancer10072990
- Registration Number
- NL-OMON33970
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
* Patients with primary or recurrent squamous cell carcinoma of the larynx in whom total laryngectomy is considered the treatment of choice.
* Glottic, subglottic or supraglottic larynxcarncer
* Tumor volume more than 2 cm3
* WHO performance: 0-2
* Patients older than 18 years
* Written informed consent
Exclusion Criteria
* Patient who does not sign the consent
* Pregnancy
* Patients younger than 18 years
* Contraindications MRI, as
o Pacemakers / ICD's (cochlear implant, baclofenpump, insulin-pump
o Severe renal insufficiency (eGFR <= 30)
o Claustrophobia
o Patients with known gadolinium allergy
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Preoperative hypoxia data acknowledged by 18F-FAZA-PET/CT and OE-MRI scan are<br /><br>compared with immunohistochemical results.</p><br>
- Secondary Outcome Measures
Name Time Method <p>No</p><br>